Anixa Biosciences Reports Progress in Breast and Ovarian Cancer Trials

The company’s breast cancer vaccine, developed alongside the Cleveland Clinic, successfully concluded its Phase 1 clinical trial. Final data indicate that the vaccine met all major primary endpoints, proving safe and well-tolerated at the maximum dose. Notably, 74% of participants demonstrated a protocol-defined immune response to the treatment, which targets human α-lactalbumin—a protein expressed in certain breast cancers.

Simultaneously, Anixa provided an update on its ovarian cancer CAR-T therapy, known as lira-cel. Currently in a Phase 1 trial with the Moffitt Cancer Center, the treatment targets the follicle-stimulating hormone receptor (FSHR). Early observations from the study are encouraging, with multiple patients surviving more than one year following treatment. The therapy utilizes chimeric endocrine receptor-T cell (CER-T) technology, which differentiates it from standard cell therapies by using the natural ligand of the FSHR receptor to bind to tumor cells.